OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.
You may also be interested in...
Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.
Vertex says it will not file data on its cystic fibrosis drug Symkevi (tezacaftor/ivacaftor) until the UK's NICE changes the way it assesses drugs.
The commercial team is on board and ready to market the first FDA-approved RNAi therapeutic patisiran for hereditary transthyretin-mediated amyloidosis.